

REMARKS

This paper is filed concurrently with the application papers requesting filing and immediate examination of a United States national application based on international application no. PCT/GB2003/005612, filed December 22, 2003, claiming priority to GB applications: 0229837.0 filed December 20, 2002; 0229835.4 filed December 20, 2002; 0229832.1 filed December 20, 2002; and 0229828.9 filed December 20, 2002. Please enter the foregoing amendments prior to calculation of the filing fee and prior to examination on the merits.

The first paragraph of the specification has been amended herein to provide updated information regarding cross-reference to related applications under 37 C.F.R. § 1.78.

A check (No. 6408) in the amount of \$1,725.00 to cover the national stage filing fees accompanies these papers, and the fees are calculated taking the foregoing amendments into account, since the amendments eliminate some multiple dependencies from the claims. No additional fees are believed to be due; however, the Commissioner is specifically authorized to charge any additional fees deemed to be necessary in connection with the filing of this paper or any of the accompanying papers, or to charge other fees necessary to complete this US filing to Deposit Account 50-0268.

The foregoing amendments to the claims are clerical in nature, e.g., they either eliminate improper multiple dependencies or clarify the claim language to aid examination without substantively changing the claim. The claims are thus presented in proper form for review in the USPTO. It is not the intention of the Applicant to abandon any of the inventive subject matter disclosed in the application as originally filed.

Claims 36 and 37 were amended to include the European Collection of Animal Cell Cultures deposit numbers. Support for the amendment is found in the paragraph bridging pages 1 and 2 of the specification.

Claim 52 has been amended to specify that the form or forms of Factor XIIa under investigation is any one or more of complexes comprising two or more molecules of Factor XIIa, Factor XIIa associated with low affinity binding partners, and Factor XIIa associated with high affinity binding partners. Support for the amendment is apparent from the original claim and original Claims 46, 47, 49, and 50, which are cancelled herein.

Claim 83 has been amended to set forth details of the assay(s) specified in Claim 70. Support for the amendment is apparent from original Claims 5, 27, 34-39 and pages 41-43 of the specification.

Support for the additional amendments is apparent in the original claims 1-93, and no new matter is added thereby.

Entry of the foregoing amendments and examination of the claims as amended are requested.

Respectfully submitted,



Leon R. Yankwich, Reg. No. 30,237
Michael R. Wesolowski, Reg. No. 50,944
Attorneys for Applicant
YANKWICH & ASSOCIATES, P.C.
201 Broadway
Cambridge, Massachusetts 02139
telephone: 617-374-3700
telecopier: 617-374-0055

Certificate of Express Mailing

The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, postage prepaid, in an envelope addressed to: **Mail Stop PCT**, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Express Mail Label No.: EV 509622200 US

June 20, 2005
date


Melanie McFadden